UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 12, 2015

 

GENOCEA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36289

 

51-0596811

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

Cambridge Discovery Park
100 Acorn Park Drive, 5th Floor

 

 

Cambridge, MA

 

02140

(Address of principal executive offices)

 

(Zip Code)

 

 (Registrant’s telephone number, including area code):  (617) 876-8191

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 2.02                   Results of Operations and Financial Condition.

 

On February 12, 2015, Genocea Biosciences, Inc. announced its financial results for the fiscal 2014 fourth quarter and  full fiscal year ended December 31, 2014.  A full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

 

Item 9.01                   Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1 Press Release issued by Genocea Biosciences, Inc. on February 12, 2015

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GENOCEA BIOSCIENCES, INC.

 

 

 

 

By:

/s/ JONATHAN POOLE

 

 

Jonathan Poole

 

 

Chief Financial Officer

 

Date: February 12, 2015

 

3


 

EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

 

Press Release issued by Genocea Biosciences, Inc. on February 12, 2015

 

4